393 related articles for article (PubMed ID: 25768104)
1. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
Weber M
Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):12-7. PubMed ID: 25768104
[No Abstract] [Full Text] [Related]
2. [More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):158-60. PubMed ID: 22780939
[No Abstract] [Full Text] [Related]
3. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
Phan AT
Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):3-5. PubMed ID: 25768101
[No Abstract] [Full Text] [Related]
4. Gut neuroendocrine tumors.
Hammond PJ; Bloom SR
Curr Ther Endocrinol Metab; 1994; 5():570-5. PubMed ID: 7704795
[No Abstract] [Full Text] [Related]
5. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
6. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
[TBL] [Abstract][Full Text] [Related]
7. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
Arnold R; Simon B; Wied M
Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
[TBL] [Abstract][Full Text] [Related]
8. [Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas].
Hansen CP; Knigge U
Ugeskr Laeger; 2008 Jun; 170(24):2145-8. PubMed ID: 18565299
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Kvols L
World J Gastroenterol; 2010 Jun; 16(24):2963-70. PubMed ID: 20572298
[TBL] [Abstract][Full Text] [Related]
10. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
[TBL] [Abstract][Full Text] [Related]
12. [Neuroendocrine tumors: the age of targeted therapies].
Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
Massironi S; Conte D; Rossi RE
Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
[TBL] [Abstract][Full Text] [Related]
14. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
15. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
Gardner-Roehnelt NM
Clin J Oncol Nurs; 2012 Feb; 16(1):56-64. PubMed ID: 22297008
[TBL] [Abstract][Full Text] [Related]
16. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
17. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Ito T; Igarashi H; Jensen RT; Takayanagi R
Fukuoka Igaku Zasshi; 2012 Jul; 103(7):131-7. PubMed ID: 22978065
[No Abstract] [Full Text] [Related]
18. Medical treatment of endocrine gastroenteropancreatic tumors.
Tomassetti P; Campana D; Nori F; Piscitelli L; Salomone L; Pezzilli R; Corinaldesi R
JOP; 2006 Jan; 7(1):145-9. PubMed ID: 16407637
[No Abstract] [Full Text] [Related]
19. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates.
Khagi S; Saif MW
JOP; 2014 Mar; 15(2):135-7. PubMed ID: 24618437
[TBL] [Abstract][Full Text] [Related]
20. Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors.
Pivonello R; Ferone D; Filippella M; Faggiano A; De Martino MC; Auriemma RS; Rota F; Lombardi G; Colao A
J Endocrinol Invest; 2003; 26(8 Suppl):82-8. PubMed ID: 15233220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
